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Abstract: Neutrophil extracellular traps (NETs) are web-like structures of decondensed extracellular
chromatin fibers and neutrophil granule proteins released by neutrophils. NETs participate in host
immune defense by entrapping pathogens. They are pro-inflammatory in function, and they act as an
initiator of vascular coagulopathies by providing a platform for the attachment of various coagulatory
proteins. NETs are diverse in their ability to alter physiological and pathological processes including
infection and inflammation. In this review, we will summarize recent findings on the role of NETs
in bacterial/viral infections associated with vascular inflammation, thrombosis, atherosclerosis and
autoimmune disorders. Understanding the complex role of NETs in bridging infection and chronic
inflammation as well as discussing important questions related to their contribution to pathologies
outlined above may pave the way for future research on therapeutic targeting of NETs applicable to
specific infections and inflammatory disorders.
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1. Introduction
Neutrophils play a key role in the body’s innate immune response constituting the first
line of defense against a wide range of pathogens. Neutrophils contribute to elimination of
the intruder by phagocytosis, degranulation of antibacterial proteins, generation of reactive
oxygen species (ROS) and the recruitment and activation of other immune cells. Moreover,
neutrophils may form neutrophil extracellular traps (NETs), which are strands of DNA
extruded by activated or dying neutrophils, decorated with various inflammatory media-
tors and represent a link between infection, inflammation, innate immunity, thrombosis
and cardiovascular disease (CVD) [1]. In response to a growing list of stimuli including
various bacterial and viral specimens, but also sterile particles such as urate crystals, neu-
trophils undergo a specialized series of reactions resulting in chromatin decondensation
and subsequent NETs formation. The DNA that comprises the backbone of these NETs
not only provides a scaffold for proteins stemming from the neutrophil itself but also for
external proteins from other sources. Examples of neutrophil-derived proteins associated
with NETs include myeloperoxidase, cathepsin G, neutrophil elastase (NE) and proteinase
3. A non-neutrophil protein associated with NETs would be, e.g., tissue factor (TF) a main
trigger of the coagulation cascade fostering thrombosis [2]. Although NETs play a beneficial
role in host defense against pathogens, there is increasing evidence that the presence of
NETs (also in chronic inflammatory conditions) triggers a cascade of unwanted side effects,
such as production of autoantibodies against the host’s DNA, tissue damage or induction
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of atherothrombotic events. In this review we will summarize recent findings of how
NETs formation initiated by bacterial or viral infections as well as in autoimmune diseases
contributes to complications of CVD. Uncontrolled NETs generation during bacterial and
viral infections could be the missing link between infections and increased CVD risk [3].
2. NETs Affecting Cardiovascular Health in Infectious Diseases
In 2004, Brinkmann and colleagues showed the association of NETs with both Gram-
positive and Gram-negative bacteria and showed bactericidal properties [4]. Since then,
NETs have emerged as important players in host defense against various bacterial and viral
infections. During infections, NETs induce entrapment, reduce dissemination and help in
killing microorganisms. Failure of NETs-induced capturing and killing of microorganisms
is associated with sepsis. NETs are prevalent during sepsis, as they control the spread of
infection, and their degradation, using recombinant DNase, leads to increased bacterial
burden (shown in mice) but at the same time leads to organ and tissue damage [5]. In
a similar study, NETs were associated with platelet aggregates, triggering microvessel
occlusion in septic mice [6]. In addition to this, NETs-induced hepatic damage was observed
in methicillin-resistant S. aureus induced sepsis. This damage was inhibited by NE or
peptidyl arginine deiminase type IV (PAD4) deficiency [7]. Similarly, inhibition of NETs
using DNase1 or neutralizing antibodies against histones tend to reduce organ damage
in a poly-microbial sepsis mouse model [8]. Acute infection with various viruses and
Gram-positive and Gram-negative bacteria leads to higher risk of CVD [9,10]. In this
section, we will focus on role of NETs in major bacterial and viral infections leading to
cardiovascular complications. The inducers of NETs formation during infection and their
role in CVD manifestation have been summarized in Table 1.
Table 1. List of pathologies involved in the manifestation of NETs-induced vascular diseases.




early secretory antigen-6 protein
Endocarditis, acute myocardial
infection, myeloid cells recruitment
to atherosclerotic lesions,
microvascular thrombosis,
thrombosis of injured heart valves,
enhanced atherosclerotic lesion size
[7,11–18]
Viral infection High levels of intracellularreactive oxygen species
Immunothrombosis, microvascular
thrombi in the lung, kidney, and




(IL) IL-1β and IL-6, IL-8, oxLDL,




Endothelial damage in SMC-rich
plaques, plaque macrophage
inflammation, increased plaque
vulnerability, enhanced lesion size
and carotid artery thrombosis
[23–32]
Thrombosis High mobility group box 1(HMGB1), hemodynamic force
Occlusion of microvessels and










2.1. Cardiovascular Manifestations of Bacterial NETs Induction
Staphylococcus aureus is a Gram-positive bacterium that causes diseases such as os-
teomyelitis, infective endocarditis, bacteremia and gastroenteritis by inducing NETs forma-
tion and severe inflammation [4,43]. S. aureus leads to conversion of NETs to deoxyadeno-
sine that exerts caspase-3-mediated cytotoxic effects on macrophages. This mechanism
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helps S. aureus to escape NETs induced entrapment [44]. Infection with methicillin-resistant
S. aureus (MRSA) was shown to induce NETs formation in liver vasculature, which leads to
liver damage [7]. NETs entrap bacterial-platelet aggregates and promote septic thrombus
formation on injured heart valves, as shown in an S. aureus-induced endocarditis rat model.
This suggests a role of NETs in bacterial biofilm production and platelet aggregation on
injured heart valves [14]. In the same study, inhibition of NETs formation by administration
of DNase1 before infecting the rats with S. aureus leads to reduction in biofilm and septic
thrombus formation [14]. Another Gram-positive bacterium, Streptococcus pneumonia, also
leads to induction of NETs formation [4]. A pneumococcal protein called α-enolase, from
S. pneumonia, interacts with neutrophil surface proteins, increases neutrophil recruitment
and induces NETs formation [11]. In a model of invasive pneumococcal disease in mice,
S. pneumonia was shown to invade the myocardium and lead to formation of microle-
sions. These microlesions in the invaded myocardium also display high neutrophil and
macrophage infiltration. Ongoing accumulation of S. pneumonia in these microlesions
induces cardiomyocyte cell death within the lesion [45].
Escherichia coli is a Gram-negative bacterium causing pathologies such as enteritis,
urinary infections, meningitis and sepsis [46]. Serum from patients with E.coli-triggered
septic shocks leads to significant NET formation by neutrophils in vitro [47]. Exposure
to E.coli-derived lipopolysaccharides (LPS) activates the coagulation system through in-
dividual histone proteins and human neutrophil DNA [48]. LPS-stimulated platelets are
shown to promote NETs formation through Toll-like receptor 4 (TLR4) activity [12], and
platelet, thrombin and NETs interactions trigger intravascular thrombus formation in
the liver microcirculation of septic mice [17]. In the same study, PAD4-deficient animals,
which have a reduced ability to form NETs, showed a significant decrease in microvas-
cular thrombosis [17]. Another study highlighted the link between acute infection, NETs
and vascular inflammation by using a mouse model of endotoxemia. Here, they induced
endotoxemia by injecting LPS to Apoe−/− mice fed with a Western diet (WD) for 4 weeks,
which resulted in accumulation of NETs along the arterial wall, recruitment of myeloid
cells to the atherosclerotic lesions and augmented lesion size [16]. Furthermore, the authors
showed that the interaction of NETs and monocytes was not regulated by a receptor but
instead by cationic histone H2a. Cationic histone H2a electrostatically interacts with the
negatively charged monocyte surface and leads to enhanced monocyte adhesion to the
arterial wall and increased recruitment to the atherosclerotic plaque. In the same study,
inhibition of NETs by Cl-amidine, a second-generation PAD inhibitor replacing the phenyl
and carboxamide groups of Cl-amidine with a biphenyl and benzimidazole group, respec-
tively, significantly reduced cell-free DNA in the plasma, eliminated the NETs in the lumen
and inhibited myeloid cell recruitment to the atherosclerotic lesion [16].
Mycobacterium tuberculosis specifically affects the respiratory system, causing tuber-
culosis. Different subspecies of mycobacterium can induce NETs when they are cultured
with neutrophils, for instance, M. tuberculosis induced NETs formation by secreting early
secretory antigen-6 protein resulting in elevated intracellular Ca2+ in neutrophils and caus-
ing necrosis [13]. NETs can effectively trap and reduce the dissemination of M. tuberculosis;
however, NETs-derived components are unable to kill M. tuberculosis [49]. Latent tuberculo-
sis infection is associated with acute myocardial infarction and may trigger cardiovascular
complications [15]. In a case study, mass spectrometry analyses of the composition of
infective endocarditis biofilm and septic thrombus showed the contribution of NETs to
the formation of tuberculous endocardiac mass formation [18]. These tuberculosis endo-
cardiac masses are space-occupying lesions in the endocardium consisting of bacterium,
platelets, fibrin, microorganisms and inflammatory cells caused by endovascular microbial
infection of intracardiac structures facing the blood. Endocardiac mass formation can
lead to endcocardial damage and valve destruction. In one case study where a patient
presented with a large mass on the anterior mitral leaflet and dense yellow areas inside
the right atrium, these areas were positive for M. tuberculosis and were sensitive to all
anti-tuberculous medications [50]. Patients with tuberculosis endocarditis were managed
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with valve replacement and anti-tuberculosis drugs [51]. Altogether, bacterial infections
promote progression of atherothrombosis or atherosclerosis possibly through induction
of NETs formation, subsequent formation of platelet–NETs aggregates and NETs-induced
cardiac damage or fostering of atherosclerotic lesion growth.
2.2. Cardiovascular Manifestations of Viral NET Induction
Many viruses such as Hemagglutinin Type 1 and Neuraminidase Type 1 (H1N1), Human
Immunodeficiency Virus (HIV) and hepatitis have either a direct or an indirect effect on
CVD. The mechanisms behind these effects are still not fully understood. In addition, NETs
involvement in CVD during viral infections has received little attention. This oversight
may be due to the fact that many viruses have developed many strategies to prevent
the formation of NETs or escape them. Therefore, they have not been investigated in
the context of viral co-morbidities such as CVD. For example, Hepatitis B virus may in-
hibit NETs release by modulating reactive oxygen species production and autophagy [52].
HIV has developed many mechanisms to evade the human immune system and can
even induce neutropenia by impairing hematopoiesis [53]. HIV also choreographs ab-
normal neutrophil behavior including chemotaxis, phagocytosis, oxidative metabolism
and pathogen-killing [54]. Neutrophils from HIV-infected individuals exhibit elevated
interleukin 12 (IL-12) secretion triggering a chronic inflammatory process [55]. As a counter
measure, HIV induces the release of the anti-inflammatory IL-10 from dendritic cells to
neutralize NETs [56]. Human IL-10 homologs have been found in the genome of DNA
viruses such as human cytomegalovirus (HCMV) and Epstein–Barr virus (EBV) [57,58].
These IL-10 homologs could suppress NETs formation in a similar manner to cellular IL-10.
Like cellular IL-10 these homologs inhibit the TLR 7 and TLR 8-signaling pathways, thus
suppressing NADPH oxidase-dependent formation of NETs [56,59]. Since the 1930s a corre-
lation between influenza infections and vascular complications has been observed [60–62].
A recent study also highlighted that excessive NETs formation, neutrophil inflammation
and delayed apoptosis is found in patients with severe influenza infection [63]. These
findings suggest that neutrophils may dominate the host response towards influenza, and
this correlates with poorer outcomes. Therefore, excessive NETs formation could also
have downstream implications such as the development of CVD. Atherosclerosis-prone
apolipoprotein E-deficient (Apoe−/−) mice are a popular model for the study of atherosclerosis
as they have a reduced lipoprotein clearance and accumulation of cholesterol ester-enriched
particles in the blood promoting the development of atherosclerotic plaques [64]. A study
has demonstrated that Apoe−/− mice infected with the influenza A virus, show direct infec-
tion of vascular endothelial cells and smooth muscle cells in atherosclerotic plaques [65].
This study further showed that influenza infection promotes inflammation, smooth muscle
cell proliferation and fibrin deposition in atherosclerotic plaques. Apoe−/− mice infected
with influenza A showed increased cell infiltration in atherosclerotic plaques compared to
uninfected Apoe−/− mice. However, wild-type infected C57BL/6 mice showed no evidence
of the same infiltration of the vascular intima [65]. This could suggest that in patients with
atherosclerosis, influenza A infections could exacerbate the disease. There is already some
evidence proposing that the influenza vaccine can reduce the risk of developing CVD [66].
Another study demonstrated that human leukocytes adhere to influenza-infected human
umbilical vein endothelial cells (HUVECs) in a viral dose-dependent manner [67]. Further
investigations on human aortic endothelial cells (HAECs) revealed that influenza virus
infections increase the expression of chemokines, including chemokine (C-C motif) ligand
2 (CCL2), CCL5, and IL-8. Furthermore, influenza infection augmented the expression of
intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM-1)
and E-selectin on human aortic endothelial cells (HAECs) and human umbilical vein en-
dothelial cells (HUVECs) [68,69]. Together, these data suggest that the influenza virus may
exacerbate atherosclerosis, as it enhances the pro-inflammatory environment and leukocyte
infiltration. Therefore, this increase in inflammation in the vasculature would likely result
in the infiltration of neutrophils and possibly the formation of NETs. The cytotoxic effect
Cells 2021, 10, 1689 5 of 21
of NETs could create endothelial dysfunction setting the stage for the development of
atherosclerosis. However, this would require further investigation.
Influenza A WSN/33(H1N1) virus can also induce host cell proteases, such as trypsin
and matrix metalloprotease 9 (MMP-9), in various organs, which may act to increase vascu-
lar permeability and viral entry in different organs [70]. As of now, the role of neutrophils in
atherosclerosis during influenza infections has not been investigated. NETs have cytotoxic
effects on endothelial cells [71] and damage the lungs in mice infected with influenza A
virus H1N1 strain PR8 [72]. Furthermore, NETs are found in the alveolar epithelium and in
small blood vessels in areas of hemorrhagic lesions in the lung, probably causing alveoli-
capillary damage [72]. A study has demonstrated that patients with severe influenza
presented with elevated NETs in the plasma, and the neutrophils from these patients
released a greater amount of myeloperoxidase-DNA (MPO-DNA) complex in response
to IL-8 [73]. Furthermore, NETs from influenza A infections in H1N1 and H7N9 patients
increased the permeability of alveolar epithelial cells [73]. It is conceivable that influenza
infections could trigger NETs in the circulatory system and either induce atherosclerosis
due to increasing permeability of vascular endothelial cells or exacerbate already estab-
lished atherosclerosis plaques. However, further research is essential to understand the
role of NETs in CVD during influenza infections.
In 2019 a novel virus, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2),
was identified which caused an atypical respiratory disease. It is a multifaceted disease
affecting the circulatory system as well as the respiratory system. Increased neutrophil
counts in COVID-19 correlate with disease severity, and poor prognosis and extensive neu-
trophil infiltration of pulmonary capillaries has been observed in autopsy studies [74,75].
The angiotensin-converting enzyme 2 (ACE2) has been identified as one of the most im-
portant receptors for the virus entry into host target cells. During hypoxia, angiotensin II
induces pulmonary vasoconstriction to restore the ventilation–perfusion imbalance, while
simultaneously inducing adverse pro-fibrotic effects. However, both vasoconstriction and
fibrosis are associated with upregulation of ACE2 [76,77]. The upregulation of ACE2 in pa-
tients with comorbidities may result in an increased viral load and spreading of infection to
extrapulmonary tissues [19]. This systemic infection is associated with higher neutrophil-to-
lymphocyte ratios in infected tissues and high levels of pro-inflammatory cytokines [78,79].
Evidence suggests that microthrombi and coagulopathy contribute to COVID-19 pathogen-
esis [78,79]. It has been demonstrated that COVID-19 increases the levels of intracellular
reactive oxygen species (ROS) in neutrophils to stimulate NETs formation [19]. Another
study has demonstrated that during COVID-19 infections, neutrophils are alternatively
activated, express more CD64 and programmed death-ligand 1 (PD-L1) [80] and could
be the reason for excessive NETs formation in COVID-19 [21]. Additional evidence has
suggested that neutrophils in severe COVID-19, guided by activated platelets, migrate into
inflamed tissue and release NETs [81–83]. A recent study showed microvascular thrombi
associated with platelet–neutrophil aggregates in the lung, kidney and the heart of COVID-
19 patients [22]. In a cohort study, plasma MPO-DNA complexes defined as NETs, platelet
factor 4, RANTES (CCL5) and selected cytokines were measured in plasma samples from
COVID-19 patients (n = 33) and age- and sex-matched controls (n = 17) [83]. This study
revealed that an increased prevalence of MPO-DNA complexes in COVID-19 patients
correlated directly with the severity of the disease. Furthermore, three COVID-19 lung
autopsies were analyzed for NETs and platelet involvement, revealing NETs-containing
microthrombi with neutrophil-platelet infiltration within these samples [83]. The latter
suggests that NETs are not only involved in the host defense against SARS-CoV-2 but
may also trigger detrimental immunothrombosis, a process understood as the interac-
tion of activated leukocytes with platelets and plasma coagulation factors resulting in
thrombotic complications of COVID-19 patients [21,84]. Others investigated how com-
plement interacts with the platelet-induced-NETs–thrombin axis during COVID-19 and
found increased plasma levels of NETs, tissue factor (TF) activity and sC5b-9 in COVID-19
patients [85]. Neutrophils isolated from COVID-19 patients had higher TF expression
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and released NETs carrying active TF. Treatment of control neutrophils with COVID-19
platelet-rich plasma generated TF-bearing NETs that induced endothelial dysfunction. The
inhibition of thrombin, NETs formation or C5aR1 blockade resulted in the attenuation of
platelet-mediated NETs-driven thrombogenicity [85]. COVID-19 serum further induced
complement activation in vitro, consistent with high complement activity found in clinical
samples, and the inhibition of complement disrupted TF expression in neutrophils [85].
Overall, these data demonstrate that complement and NETs may play an important role in
COVID-19-associated immunothrombosis. Patients hospitalized with COVID-19 exhibited
elevated levels of neutrophil activation and NETs formation, which are associated with
higher risk of death due to thrombotic complications in these patients [86].
These observations highlight the urgent need for further research on the potential
relationship between NETs-induced thrombosis in COVID-19. As the level of neutrophils
and NETs in patients with COVID-19 has a direct correlation with severity, therapeutics
targeting NETs could improve the outcome [87]. Hopefully this will encourage future
research to investigate the role of NETs in other viral infections and their influence on CVD.
3. Implications of NETs Formation in CVD
In recent years, NETs emerged as key players in the progression of CVD. Aging,
being one of the major risk factors for CVD, is also associated with a higher susceptibility
of neutrophils to form NETs, cardiac fibrosis, heart failure and atherosclerosis. In an
experimental model of cardiac fibrosis, higher NETs formation was observed in older
C57BL/6J mice (20–27 months) as compared to younger mice of 8–16 weeks of age [88].
In the same study, PAD4 deficiency or DNase1 treatment (to inhibit NETs) resulted in
diminished platelet–neutrophil complexes and reduced fibrosis in the myocardium of
older mice [88]. Mitochondrial oxidative stress in myeloid cells in aged mice (36 weeks
old) led to enhanced NETs in the atherosclerotic plaque and contributed to enhanced
atherosclerosis [89]. Presence of NETs in atherosclerotic plaques implies an important role
of NETs in atherosclerosis [90]. Analyses of blood samples drawn from patients before
and after percutaneous coronary intervention (PCI) suggested high levels of NETs markers
such as double-stranded (ds)DNA and MPO-DNA after PCI. Higher circulatory levels of
dsDNA at day 1 after PCI were associated with large infarct size, and their prevalence
indicates adverse cardiovascular complications [91]. However, dsDNA could be associated
with other cell types, and further NETs-specific investigations will be required. In another
study, NETs and NET components are shown to have pro-thrombotic properties as they
promote coagulation by inducing fibrin network formation [92]. Therefore, in this section,
we will focus on their induction, role in vascular manifestation (Table 1) and involvement
in atherosclerosis (Figure 1) and vascular thrombosis (Figure 2).
3.1. NETs in Atherosclerosis
Atherosclerosis is a chronic inflammation of the arterial wall, initiated through luminal
endothelial cell activation and damage, intimal accumulation of low-density lipoproteins
(LDLs) and recruitment of monocytes, dendritic cells, neutrophils and T-lymphocytes to
the intimal layer. Infiltrated monocytes mature into macrophages and eventually lead to
foam cell formation, thus leading to progression of atherosclerotic plaque formation [93].
High neutrophil numbers in atherosclerotic plaques in the coronary arteries was
reported to cause plaque erosion and rupture [94]. Another study focusing on monocyte-
depleted Lysmegfp/egfp Apoe−/− mice after four weeks of WD and on human atherosclerotic
plaques obtained by endarterectomy have reported the presence of NETs in mouse and hu-
man atherosclerotic plaques [90]. Another study showed the differential presence of NETs
in upstream and downstream regions of human samples isolated during carotid endarterec-
tomy. They further established that patients with high serum levels of autoantibodies
against apolipoprotein A-1 (ApoA1) presented with a higher signal for citrullinated histone
H3 outside of neutrophils when compared to serum negative patients. This indicates that
expression of NETs elements could be influenced by circulating levels of anti-ApoA-1 [26].
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NETs formation can also occur in early stages of atherosclerosis induced by cholesterol crys-
tals leading to higher transcription of pro-inflammatory mediators such as IL-1β and IL-6
from primed lesional macrophages [23]. IL-1β and IL-6 can further activate T helper cell 17
(Th17) cells and lead to accelerated recruitment of immune cells into the atherosclerotic
plaque (Figure 1) [23].
Analyses of smooth muscle cell rich fibrous caps in mouse and human atherosclerotic
plaques showed the presence of NETs releasing neutrophils. Furthermore, the super-
natant of activated smooth muscle cells attracts neutrophils via CCL7 and stimulates NETs
formation. This NETs induction resulted in histone H4 release, which leads to smooth
muscle cell lysis and eventually participates in a vulnerable plaque phenotype. Neutral-
ization of histone H4 in hypercholesterolemic mice resulted in enhanced lesional smooth
muscle cell content and generated reduced vulnerability in the plaques [29]. This un-
derlines the role of NETs in inducing vulnerable plaques, which could result in plaque
rupture-induced thrombotic complications (Table 1). Patients with atherosclerosis show
high serum levels of IL-8, a pro-inflammatory cytokine, and NETs in blood. IL-8 interacts
with the CXC chemokine receptor 2 (CXCR2) on neutrophils and induces NETs forma-
tion. CXCR2 depletion by using CXCR2 blocking antibody inhibited NETs formation and
alleviated atherosclerosis progression in Apoe−/− mice fed with WD for 12 weeks [24].
In another study, exosomes extracted from oxidized LDL treated HUVECs resulted in
metastasis-associated lung adenocarcinoma transcript 1 (MALAT1)-induced NETs formation
and atherosclerosis progression [27]. Additionally, modified lipids such as oxidized LDL
co-incubated with HL-60-derived neutrophils and human peripheral blood neutrophils
lead to significantly higher NETs formation [25]. In turn, NETs formation can induce dam-
age to endothelial cells because in smooth muscle cell rich plaques apoptotic endothelial
cells were correlated with more NETs-rich regions (Table 1) [28]. Cathepsin G (one of the
components of NETs) and cathelicidin-related antimicrobial peptides can induce activation
of monocytes and dendritic cells, fostering monocyte adhesion to endothelial cells and
eventually influencing their recruitment to the atherosclerotic lesions [95,96]. NETs can
also stimulate macrophages to produce pro-inflammatory cytokines, which result in Th
17 cell activation and a significant increase in immune cell recruitment to the atheroscle-
rotic plaque [97]. Moreover, repetitive social defeat exposure in Apoe−/− mice promoted
atherosclerosis by promoting NETs formation within the plaque. DNase I treatment to
inhibit NETs in these animals resulted in reduction of pro-atherogenic effects of repet-
itive social defeat exposure [98]. NETs in atherosclerotic plaques are associated with a
pro-inflammatory phenotype of macrophages (Table 1). Resolution of NETs by injecting
DNase 1 to male Ldlr–/– mice fed with WD for 16 weeks reduced NETs-induced plaque
macrophage inflammation and suppressed atherosclerosis progression in diabetic mice [31].
Another study suggests that inflammasome activation could lead to increased neutrophil
recruitment and NETs formation in atherosclerotic plaques. Cholesterol transporters ATP
Binding Cassette (ABC) A1 and G1 promote cholesterol efflux to high-density-lipoprotein
(HDL), and Abca1/g1 deficiency in myeloid cells leads to cholesterol accumulation. Choles-
terol accumulation in myeloid cells activates the NLRP3 inflammasome, which enhances
neutrophil accumulation and NETs formation in atherosclerotic plaques. NLRP3 deficiency
shows to reduce atherosclerotic lesion size in myeloid Abca1/g1-deficient Ldlr−/− mice [30].
In a photochemical injury thrombosis model, Apoe−/− mice were treated for 11 weeks
with Cl-amidine to block NETs formation, which resulted in reduced atherosclerotic lesion
size and prolonged induction of carotid artery thrombosis in these animals [32]. Addi-
tionally, in the same study, combined administration of chloramidine and a neutrophil
depletion antibody into Apoe−/− mice did not affect the lesion size. Another study used
PAD4-deficient bone marrow cells to halt the ability of neutrophils to undergo NETs forma-
tion. This hematopoietic PAD4-deficiency was shown to inhibit intimal NETs formation
in the carotid arteries of eight-week-old Ldlr−/− male mice fed with modified WD diet
and led to protection of intimal integrity of the endothelium. Thrombus formation was
also observed on the intimal surface in mice reconstituted with wild-type bone marrow as
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compared to those with Pad4−/− bone marrow [99]. In a similar study, myeloid-specific
deletion of PAD4 substantially diminished NETs formation and NETs-induced atheroscle-
rosis in the aorta of Pad4−/− mice fed with WD for 10 weeks [100]. Targeted delivery of
GSK484, a PAD4 inhibitor, via collagen IV-targeted nanoparticles to reach lesions with
features of superficial erosion, resulted in decreased NETs accumulation at the sites of
intimal injury in 8-week-old Apoe−/− mice [101]. These findings point towards a crucial
role of NETs and their inhibition in lesion size formation and thrombotic complications
during atherosclerosis.
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the induction of NETs formation; (Right): Close up atherosclerotic lesion; Neutrophils activated e.g., by bacterial and
viral pathogens may undergo NETs formation thereby activating leukocytes, platelets and endothelial cells creating a
pro-inflammatory milieu triggering lesion growth. Lesional NETs may be induced by pathogens or CCL7 and initiate a
IL-1b ta r lease or a Th17 response al ogether driving lesion expa sion. (made w th biorender.com, 4 June 2001).
3.2. NETs-Induced Thrombosis
Numerous studies have indicated the presence of NETs in arterial and venous thrombi.
NETs formation during thrombosis is thought to be initiated by hypoxia-induced release
of von Willebrand factor (vWF) and P-selectin from the endothelium, which recruits
and activates neutrophils that form NETs (Figure 2) [102–104]. NETs in return activate
endothelial cells and induce VCAM-1 and ICAM-1 [102], thus providing a scaffold for
adhesion of platelets, red blood cells, fibrinogen, vWF and fibronectin [92]. This scaffold
not only forms a structural basis, but many of its components can also actively trigger
platelet activation and blood coagulation. Furthermore, NETs also induce TF expression
on the endothelial cell surfaces, thereby accelerating plasma clotting in vitro. Elevated
TF expression in neutrophils and the release of NETs decorated with TF have been found
not only in COVID-19 but also in patients with sepsis [47], ST-segment elevation acute
myocardial infarction (STEMI) [105] and SLE [106]. This suggests that NETs activate
the extrinsic pathway of coagulation, which is a shorter coagulation pathway of fibrin
formation. It includes activation of coagulation factor VII to factor VIIa and thereby
generation of factor Xa. Factor Xa further contributes to fibrin formation by activating
prothrombin to thrombin with the help of Factor V as a cofactor [107].
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Other component of NETs, such as histones H3 and H4, are highly cytotoxic to en-
dothelial cells [108] and smooth muscle cells [29] and induce platelet aggregation via
Toll-like receptor TLR 2 and 4 [92,108], which eventually promotes thrombin genera-
tion [92]. Histones further endorse thrombin generation by binding to thrombomodulin
and prevent the activation of activated protein C (APC) [109]. NE and cathepsin G, which
are also present on NETs, enhance TF- and factor XII-driven coagulation via proteolysis
of tissue factor pathway inhibitor (TFPI) [110]. NETs also directly bind plasma factor XII
and, with the cooperation of platelets, support its activation to plasma factor XIIa [111].
NETs can contribute towards fibrin formation through the intrinsic pathway of coagulation.
NETs–microparticle complexes can also induce NETs-induced thrombin generation via the
intrinsic pathway of coagulation since their incubation with factor XII-deficient plasma
reduced NETs-induced thrombin generation by 97% [112]. Upon exposure to pathogens,
NETs together with platelets and immune cells lead to the formation of intravascular
thrombi that could entrap the pathogen and limit its dissemination (Figure 2). Intravas-
cular NETs formation can lead to fibrin-independent immune cell-mediated occlusion of
microvessels and cause massive cell death in affected areas [35,36]. Inhibitor of NETs,
for instance, via injection of DNase 1 and DNase1-like 3, prevent vascular occlusion by
degrading NETs clots during chronic neutrophilia [113]. In addition to this, patients with
acute thrombotic microangiopathies also show low levels of plasma DNase 1 [114]. In line
with this, N-deficient mice also show differences in thrombus formation, hence suggesting
a role of NETs in vascular thrombosis [110].
In heparin-induced thrombocytopenia (HIT), which can clinically manifest in arte-
rial and venous thromboembolic complications, heparin/platelet factor 4/IgG antibody
complexes lead to platelet activation mediated through binding of platelets to FcγRIIa
receptors, which consecutively propagates a massive auto-amplifying coagulation activa-
tion, by release of procoagulant factors. Recent data now also show that neutrophils can
be directly activated by heparin/platelet factor 4/IgG antibody complexes through their
FcγRIIa receptors, which also propagates NETs formation [115]. In line, the latter pathway
cannot be inhibited by anti-CD62p and anti-CD162 antibodies to suppress NETs formation,
but NETs generation and thrombus formation are abrogated in FcγRIIa+/heparin-platelet
factor 4+ mice lacking PAD4 [115]. These results show that thrombosis in HIT, at least in
part, is mediated through neutrophil activation and NETs induction.
Venous thromboembolism (VTE) is composed of deep vein thrombosis (DVT) and
pulmonary embolism (PE). Various studies account for the presence of NETs in venous
thrombi (Table 1). One study on iliac veins with balloon catheterization in baboons revealed
an extracellular chromatin core in the thrombus. During thrombus formation, plasma levels
of cell-free DNA were also elevated [92]. Similar findings were observed in an inferior vena
cava DVT mouse model induced by flow restriction in mice [111,116]. In another study, 16
VTE thrombi originating from 11 patients with DVT, PE and/or an inferior vena cava filter
thrombus were analyzed [117]. After scoring the organization stage based on the Masson
trichrome staining, consecutive sections were analyzed for the presence of neutrophils
and citrullinated histone H3 as a marker of extracellular NETs structures. These findings
indicated that NETs formation takes place during recruitment of neutrophils to the thrombi
and are replaced by collagen fibers at a later stage of thrombus formation.
NETs are also abundant in coronary thrombi, as observed and analyzed in patients
with acute myocardial infarction [37,118]. In another study, investigating patients with
stent thrombosis after percutaneous coronary intervention, neutrophils and NETs were
abundantly found in the retrieved thrombi [119]. Analyses of NETs in coronary thrombi
collected from ST-elevation acute coronary syndrome patients, via coronary thrombectomy,
correlated positively with infarct size (Table 1) and negatively with ST-segment resolu-
tion [37]. Further, 68 ischemic stroke thrombi showed abundance of NETs [120]. Together,
these findings point towards the potential clinical importance of NETs in arterial and
venous thrombosis.
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4. Cardiovascular Manifestations of Sterile NETs Induction
An autoimmune disease describes a pathophysiology where the host immune system
attacks cells and or tissue of host origin (self) [121]. The diseas can affect one or multiple
parts of the body. Common symptoms include fever and tiredness, but autoimmune dis-
ease can also be pro-inflammatory [121]. This pro-inflammatory environmen induced
by the disease can in turn trigger he development f NETs [122]. Key nducers of NETs
formation and related vascular manifestations to enhance CVD risk are shown in Table 1.
System c lupus ery hem tosus (SLE) is an autoimmune disease char cterized by a loss of
tolerance to self-antig ns, abnormal T and B cell responses, autoantibody pro uction and
c rrelates with a high r risk of CVD, especially atherosclerosis [123]. A subset of imma-
ture neutrophils, called low-density granuloc tes (LDGs), po sessing a proinfla atory
phenotype may contribute to disease pathogenesis [124]. NET formation is also reported
in SLE in vivo and was described in the kidn y, skin and peripheral blo d [38]. Thus, it is
conceivable that NETs formation due to SLE, especially in the arteries, c uld activate the
endothelium and initiate ather sclerotic lesion formation. Given that active neutrophils
an NETs are in abundance in SLE patients, and that SLE patients have a higher risk of
CVD, NETs could be an important link in this detrimental relationship.
Neutrophils have been described to have a multitude of irregularities in individuals
with SLE. These neutrophils have impaired phagocytic potential [125,126] are unable to be
cleared by the C1q/calreticulin/CD91-mediated apoptotic pathway [127] and show unchar-
acteristic oxidative activity [128,129]. Of note, SLE has a distinct granulocyte population
of neutrophil LDGs [130], which promote the production of proinflammatory cytokines,
including type I interferons (IFN-I), and cause endothelial cell damage (Table 1) [38,124].
These LDGs are capable of forming NETs, even in the absence of further stimulation, and
are protected from degradation by nucleases [38,39,131]. NETs further promote plasmacy-
toid dendritic cells to increase production of IFN-α [39]. Moreover, they trigger the NLRP3
inflammasome in macrophages to enhance IL-1β and IL-18 production [131]. Together, this
pro-inflammatory environment results in endothelial damage and dysfunction known to
trigger atherosclerosis [38,42]. MMP-9 released by LDGs during NETs formation has been
demonstrated to impair murine aortic endothelium-dependent vasorelaxation and induce
endothelial cell apoptosis [40]. The inhibition of MMP-2 activation restored endothelial
function and reduced NETs-induced vascular cytotoxicity [40]. This further highlights the
capability of NETs in SLE to incite vascular endothelial dysfunction, which could result
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in the development of atherosclerosis. Another possible proatherogenic mechanism of
NETs in SLE is the NETs-derived MPO/NADPH oxidase (NOX)/nitric oxide synthase
(NOS)-generated oxidative species, which are elevated in SLE [42]. This could generate
dysfunctional HDL in SLE as it may take place in the circulation rather than the vascular
wall [132,133]. Due to its particle size, it is conceivable that HDL can be trapped by NETs in
the blood vessel lumen, endothelium or sites of inflammation, rather than in subendothelial
atherosclerotic lesions [90]. NETs-mediated entrapment of HDL may lead to a dysfunc-
tional lipoprotein, impairing cholesterol efflux capacity and promoting proinflammatory
responses in blood vessels. Taken together, these data suggest that NETs could either
directly trigger or exacerbate atherosclerosis in SLE, as the formation of NETs in the vas-
culature could cause endothelial dysfunction and subsequent atherogenesis (Table 1) [41].
Alternatively, NETs can indirectly trigger or exacerbate by disruption of the cholesterol
efflux by entrapping HLD and promoting proinflammatory responses in blood vessels,
leading to atherosclerosis [41]. Furthermore, NETs in SLE could contribute to the formation
of thrombi, as revealed in prothrombotic NZM2328 mice, which rapidly form carotid
thrombi after photochemical injury of the endothelium. The latter was inhibited if NETs
formation was blocked, either with DNase1 or a PAD inhibitor, and resulted in decreased
formation of thrombi [134]. Thus, in autoimmune diseases where there is an excess of NETs
formation, the risk of thrombus formation could be increased.
Whether or not infections, either viral or bacterial, in patients with an autoimmune
disease such as SLE would have an effect on CDV is debatable. No study has investigated
CVD in patients with autoimmune diseases during an infection. Hence, it is not clear
if an infection would exacerbate the detrimental role NETs in a patient with an autoim-
mune disease and CVD. Infection could also change the phenotype of the NETs, reducing
its impact on CVD or vice versa. Future work would be needed to better understand
this phenomenon.
Rheumatoid arthritis (RA) is a chronic systemic disease characterized by joint inflam-
mation and bone destruction. Evidence suggests that NETs are involved in the pathogenesis
of RA [135]. For example enhanced NETs formation has been observed in circulating and
synovial fluid in RA patients compared to healthy controls and from patients with os-
teoarthritis [135]. Neutrophils infiltrated RA synovial tissue, rheumatoid nodules and skin,
and NETs abundance correlated with the presence of autoantibodies to citrullinated anti-
gens (ACPA) and with systemic inflammatory markers [135]. CVD risk is increased in RA,
but there is limited research on the involvement of NETs in atherosclerosis in patients with
RA. A case–control study of patients with RA and new-onset coronary artery disease (CAD)
(n = 75) was compared to an age-and sex-matched control group with newly diagnosed
CAD (n = 128) [136]. This study demonstrated that patients with RA were more likely
to have multivessel coronary involvement compared to the control group. There was no
significant difference between the cohorts with regards to risk factors for CAD including
diabetes, hypertension, hyperlipidemia and smoking history. However, until now it is
not clear if NETs in lesions from RA patients differ from the ones found in atherosclerotic
lesions and how RA NETs influence CVD and atherosclerosis.
Another study has demonstrated that self-DNA, possibly released during NETs forma-
tion, and an increased expression of the antimicrobial peptide Cramp/LL37 in atheroscle-
rotic lesions may drive atherosclerosis [137]. Plasmacytoid dendritic cell depletion and
cramp-deficiency in bone marrow of Apoe−/− mice resulted in the attenuation of atheroscle-
rosis and anti-ds DNA antibody titers [137]. Thus, self-DNA and cramp could act to
stimulate a plasmacytoid dendritic cell-driven pathway of autoimmune activation and
the generation of anti–double-stranded-DNA antibodies to exacerbate atherosclerosis
lesion formation.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is used to
describe group of autoimmune diseases characterized by destruction and inflammation of
small vessels. The presence of NETs was recently demonstrated in renal tissue of patients
with AAV (Figure 3) [138]. However, the risk of CVD in AAV is poorly quantified. A
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meta-data analysis of observational studies showed that there is an increased risk of CVD
in patients with AAV [139]. However, NETs have been suggested to play a role in ANCA-
associated thrombotic events, as thrombi obtained from ANCA vasculitis patients are rich
in both NETs and histone citrullination [140,141]. NETs could play a dominant role in this
relationship, but further research is required to reveal a causative correlation and more
insight into mechanistic pathways.
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Diabetes is a low-grade inflammatory autoimmune disease, and complications such as
endothelial dysfunction, hyperreactivity of platelets and elevated levels of pro-coagulant
mediators are common [142,143]. Neutrophils can infiltrate the pancreas in patients with
type 1 diabetes (T1D) and play a role in the onset and the progression of T1D [144,145].
Studies have also demonstrated that neutrophils from T2D patients produced NETs at
a greater rate than healthy controls [146]. Pancreas-residing neutrophils are capable of
forming NETs [147], and studies evaluating neutrophil count in patients with T1D reveal
a negative correlation between neutrophil counts and NE and proteinase 3 levels and
activity increase, suggesting enhanced NETs formation [144,145,148,149]. The expression of
PAD4 in neutrophils is increased in patients with both T1D and T2D compared to healthy
controls, and in PAD4−/− mice NETs formation was reduced [150]. This highlights PAD4
as a potential therapeutic target to interfere with NETs formation. Clots from the citrated
plasma of patients with diabetes mellitus showed greater prothrombotic effects than clots
from the control [151]. Thus, NETs in diabetes could contribute greatly to the formation of
thrombosis in diabetic patients.
A recent study in Ldlr−/− mice fed a WD for 16 weeks found that NETs+ plaques
had upregulated NLRP3 inflammasome and glycolysis pathways, as observed by tran-
scriptomic profiling [31]. This study also found that the occurrence of NETs declined in
non-diabetic mice when hyperlipidemia was reduced followed by resolution of atheroscle-
rosis. However, NETs persisted in diabetic mice under hyperglycemic conditions, exacer-
bating macrophage inflammation and impairing resolution. Diabetic mice treated with
DNase 1 reduced plaque NETs content and macrophage inflammation, allowing for lesion
regression. This suggests that NETs in diabetes can exacerbate atherosclerotic lesions,
and DNase could be a potential therapeutic treatment in diabetes to reduce the risk of
CVD. There is a strong correlation of T1D and T2D patients with CVD risk; one reason
for this correlation is diabetic vascular complications induced by hyperglycemia, known
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to enhance ROS formation and lipotoxicity [152]. It could also be possible that the hyper-
glycemic conditions themselves trigger NETs formation spontaneously via the NADPH
oxidase-dependent pathway [153], and increased ROS activity and lipotoxicity cause vas-
cular damage [154,155]. A correlation between the occurrence of diabetes-induced organ
damage, such as nephropathy or atherosclerosis, and cell-free DNA has been shown [156].
Additionally, it was shown that histone concentrations in plasma directly correlate with
blood glucose levels [156]. However, a contrasting study has demonstrated that high glu-
cose impairs NETs formation creating extracellular DNA lattices, which were short-lived
and unstable, leading to rapid erosion [157]. The same study also showed that neutrophils
induce NETs in an autocrine fashion by release of IL-6; however IL-6, failed to induce
NETs in a high-glucose environment. Nevertheless, when glycolysis was inhibited in vitro,
using 2-deoxyglucose (2-DG) it restored both LPS and IL-6 stimulated NETs formation
in a high-glucose milieu. Yet, high-dose glucose and hyperglycemia were also shown to
increase the release of NETs [156]. The differences in these results could be due to differing
incubation times, as studies have demonstrated that acute glucose fluctuations, and not
sustained chronic hyperglycemia, resulted in oxidative stress and were associated with the
development of microvascular complications in T2D patients [158,159]. Thus, glycemic
fluctuation in T2D may trigger NETs formation and cause or exacerbate CVD; however,
further research is needed to investigate this hypothesis. Further research is needed to bet-
ter understand the role of NETs in T2D, as in vitro results also showed that hyperglycemia
could impair and delay NETs formation [157].
Psoriasis is a chronic, immune-mediated disease manifesting mainly as skin lesions
and affects 2–3% of the world population [160,161]. Psoriasis is associated with systemic in-
flammation, similar to CVD, chronic obstructive pulmonary diseases and T2D mellitus [162].
One important mediator in psoriasis is lipocalin-2 (LCN2), which is an antimicrobial pro-
tein and adipokine associated with insulin resistance, obesity and atherosclerosis [163].
Serum LCN2 levels are elevated in psoriatic patients [163], and both granulocytes and ker-
atinocytes, residing in the epidermis, secrete LCN2, driving the chemotaxis of neutrophils
and sustaining NETs formation, thereby maintaining the psoriatic inflammation [164].
Regarding psoriasis, neutrophils release IL-17 in the process of forming NETs, which sig-
nificantly contribute to IL-17-related endothelial dysfunction in both atherosclerosis and
keratinocyte proliferation in psoriasis [165]. The latter could explain why atherosclerosis is
associated with psoriasis [166]. Secukinumab, a monoclonal anti-IL-17 antibody, can clear
the neutrophils in the epidermis and can improve psoriasis [167]. Moreover, secukinumab
also had a beneficial effect on CVD risk by maintaining endothelial homeostasis in patients
with psoriasis [168]. Beneficial effects of secukinumab in psoriasis patients may stem from
the global clearance of neutrophils; however, the activity of NETs in psoriatic patients with
CVD that are treated with secukinumab have not been investigated.
5. Conclusions
Neutrophils, as an essential component of the innate immune system, play a crucial
role in the control of infectious diseases. In addition, they are involved in the pathogenesis
of various inflammatory diseases. NETs formation may foster chronic inflammation,
thereby promoting cardiovascular and autoimmune diseases, which in turn makes them
an interesting therapeutic target. However, using therapeutic approaches such as DNAse I
treatment to disrupt NETs remain controversial. Alternative lines to interfere or block NETs
formation could be inhibition of PAD4, histone neutralization, ROS scavenging or partial
clearance of neutrophils. Nevertheless, all the latter are still not sufficiently understood to
reach a clinical state. Hence, a better understanding of NETs function and the balance of
NETs induction versus inhibition is needed to move one step further into patient-tailored
treatment approaches.
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